Halozyme Therapeutics Inc. (HALO) Trading Up 3.3%
Halozyme Therapeutics Inc. (NASDAQ:HALO) rose 3.3% during trading on Tuesday . The company traded as high as $12.75 and last traded at $12.48, with a volume of 1,418,924 shares traded. The stock had previously closed at $12.08.
HALO has been the subject of a number of research analyst reports. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, September 8th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $15.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, June 23rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 target price on shares of Halozyme Therapeutics in a research report on Monday, June 6th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company’s stock. Halozyme Therapeutics currently has an average rating of “Buy” and a consensus target price of $16.11.
The stock’s 50 day moving average price is $10.44 and its 200 day moving average price is $9.78. The firm’s market capitalization is $1.59 billion.
Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. Halozyme Therapeutics had a negative net margin of 44.90% and a negative return on equity of 234.15%. The company earned $33.30 million during the quarter, compared to analysts’ expectations of $29.94 million. During the same quarter in the prior year, the company posted $0.02 earnings per share. Halozyme Therapeutics’s revenue for the quarter was down 23.3% compared to the same quarter last year. On average, analysts forecast that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. Norges Bank purchased a new stake in Halozyme Therapeutics during the fourth quarter worth approximately $19,156,000. IFP Advisors Inc boosted its stake in Halozyme Therapeutics by 300.8% in the first quarter. IFP Advisors Inc now owns 11,366 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 8,530 shares during the last quarter. Teachers Advisors Inc. boosted its stake in Halozyme Therapeutics by 357.1% in the first quarter. Teachers Advisors Inc. now owns 706,111 shares of the biopharmaceutical company’s stock worth $6,687,000 after buying an additional 551,645 shares during the last quarter. Franklin Resources Inc. boosted its stake in Halozyme Therapeutics by 22.2% in the first quarter. Franklin Resources Inc. now owns 2,219,933 shares of the biopharmaceutical company’s stock worth $21,022,000 after buying an additional 403,645 shares during the last quarter. Finally, BlackRock Group LTD boosted its stake in Halozyme Therapeutics by 11.2% in the first quarter. BlackRock Group LTD now owns 128,945 shares of the biopharmaceutical company’s stock worth $1,221,000 after buying an additional 12,956 shares during the last quarter. 80.41% of the stock is owned by institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.
Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.